|
Fernandez-Velasco JI, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gascon-Gimenez F, Sainz de la Maza S, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodriguez-Martin E, Roldan E, Villarrubia N, Saiz A, Blanco Y, Diaz-Perez C, Valero-Lopez G, Diaz-Diaz J, Aladro Y, Brieva L, Iniguez C, Gonzalez-Suarez I, Rodriguez de Antonio LA, Garcia-Dominguez JM, Sabin J, Llufriu S, Masjuan J, Costa-Frossard L, Villar LM. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Front Immunol. 2022 Mar 21;13:842354. doi: 10.3389/fimmu.2022.842354. eCollection 2022. PubMed PMID: 35386690; PubMed Central PMCID: PMC8977599.
AÑO: 2022; IF: 7.3
|
35386690
|
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. PubMed PMID: 35483387.
AÑO: 2022; IF: 48.0
|
|
Mutukula N, Man Z, Takahashi Y, Iniesta Martinez F, Morales M, Carreon-Guarnizo E, Hernandez Clares R, Garcia-Bernal D, Martinez Martinez L, Lajara J, Nunez Delicado E, Meca Lallana JE, Izpisua Belmonte JC. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis. Stem Cell Res. 2021 May;53:102319. doi: 10.1016/j.scr.2021.102319. Epub 2021 Apr 15. PubMed PMID: 33894548.
AÑO: 2021; IF: 1.587
|
|
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallstrom E, Zhang X, Mares M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. PubMed PMID: 34418400; PubMed Central PMCID: PMC8434816.
AÑO: 2021; IF: 59.935
|
|
Meca-Lallana J, Garcia-Merino JA, Martinez-Yelamos S, Vidal-Jordana A, Costa L, Eichau S, Rovira A, Brieva L, Aguera E, Zarranz AR. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegener Dis Manag. 2021 Jun;11(3):251-261. doi: 10.2217/nmt-2020-0049. Epub 2021 May 10. PubMed PMID: 33966475.
AÑO: 2021
|